LLY
988.33
+0.72%↑
JNJ
240.32
+0.33%↑
ABBV
229.95
-0.9%↓
NVS
159.76
-0.49%↓
AZN
194.37
-1.51%↓
LLY
988.33
+0.72%↑
JNJ
240.32
+0.33%↑
ABBV
229.95
-0.9%↓
NVS
159.76
-0.49%↓
AZN
194.37
-1.51%↓
LLY
988.33
+0.72%↑
JNJ
240.32
+0.33%↑
ABBV
229.95
-0.9%↓
NVS
159.76
-0.49%↓
AZN
194.37
-1.51%↓
LLY
988.33
+0.72%↑
JNJ
240.32
+0.33%↑
ABBV
229.95
-0.9%↓
NVS
159.76
-0.49%↓
AZN
194.37
-1.51%↓
LLY
988.33
+0.72%↑
JNJ
240.32
+0.33%↑
ABBV
229.95
-0.9%↓
NVS
159.76
-0.49%↓
AZN
194.37
-1.51%↓
24h
Current
Min
5.83
Max
6.53
Income | -73M -99M |
|---|---|
Sales | 9.1M 11M |
Profit margin | -876.339 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +163.41% upside |
Next Earnings | 11 May 2026 |
|---|
Market Cap | 377M |
|---|---|
Previous open | 1.81 |
Previous close | 6.39 |
Past performance is not a reliable indicator of future results.
8 May 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 16.2 USD 163.41%
High 18 USD
Low 14 USD
Based on 5 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
5 ratings
5
Buy
0
Hold
0
Sell
Based on 5 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
Operating profit
$